Parmantier & Cie. sets EUR 21 price target on Lanxess, rates shares Buy (spec.)
Bitget2026/10/06 14:30Parmantier & Cie. initiated coverage on Lanxess with a Buy (spec.) rating in its “European Chemicals: The 2027 Cycle” report. The research set a 12-month price target of EUR 21 for the stock, dated Oct. 6, 2026. The firm said the next upcycle may hinge on restructuring, capacity rationalization, deleveraging, portfolio separation, operating leverage. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lanxess AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27018) on October 06, 2026, and is solely responsible for the information contained therein.
- Parmantier & Cie. initiated coverage on Lanxess with a Buy (spec.) rating in its “European Chemicals: The 2027 Cycle” report.
- The research set a 12-month price target of EUR 21 for the stock, dated Oct. 6, 2026.
- The firm said the next upcycle may hinge on restructuring, capacity rationalization, deleveraging, portfolio separation, operating leverage.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300
Crypto prices
More
